Legal Representation
Attorney
Donna J. Bunton
USPTO Deadlines
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 5, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 5, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Nov 3, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 2, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Oct 25, 2022 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Nov 2, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 25, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 6, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 4, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| May 4, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| May 4, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 6, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 4, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 4, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 4, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 7, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 5, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 5, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 5, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 7, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 5, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 5, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 5, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 23, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 5, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 10, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 10, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 19, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 31, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 4, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 3, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 3, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 25, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 25, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 25, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 22, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 9, 2019 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Sep 6, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 26, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant
Class 042
Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS
Additional Information
Pseudo Mark
AIM BIO TECH
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOTECH"